Literature DB >> 2606640

Changes in incidence of hepatitis B in Ireland from 1970-1987.

A G Shattock, L Jones, M O'Mahony, I B Hillary.   

Abstract

This paper analyses data on 2,226 cases of Hepatitis B virus (HBV) infection detected during the years 1970 to 1987. Of those where information on risk-group was available (1,301), infection among intravenous drug-abusers accounted for the largest proportion (49%). Most became infected during and since an outbreak of hepatitis B and Delta hepatitis which originated in this group in 1980. A comparison of the data before and after the start of the outbreak among drug-abusers shows a marked increase in the number of HBV infections in non drug users, including haemophiliacs, homosexuals and health-care staff, and a dramatic decrease in hepatitis B following blood transfusion. A larger group (165 cases), many of whom are long-term healthy hepatitis B surface antigen carriers, were patients in institutions for the mentally handicapped (IMH). Most were detected recently during pre-vaccination sampling programmes. Others affected included visitors to and from high-incidence areas, tattooed persons, dialysis patients, persons born to infected mothers, and members of the security forces dealing with drug-abusers. In all, 8.4% of the hepatitis B cases detected were found to be carriers and 67% of these remained carriers in 1987 The mean duration of carriage was 3.25 years. Intravenous drug-abusers and IMH patients constituted the two largest groups of carriers. The running-three-yearly mean incidence of new cases of hepatitis B has levelled off below the peak of 1981. Although the number of cases among drug-abusers has apparently decreased, the number of cases among non drug-abusing groups has increased by 50%. (ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2606640     DOI: 10.1007/bf02943614

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  10 in total

1.  Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection.

Authors:  S Krugman; J P Giles; J Hammond
Journal:  JAMA       Date:  1967-05-01       Impact factor: 56.272

2.  Hepatitis B antigen (HBAg) in the Republic of Ireland: distribution of ad and ay subtypes.

Authors:  A G Shattock; H F Gorry
Journal:  Ir J Med Sci       Date:  1974-07       Impact factor: 1.568

3.  Hepatitis-associated (Australia) antigen in the Republic of Ireland: a preliminary report.

Authors:  A G Shattock
Journal:  Ir J Med Sci       Date:  1974-05       Impact factor: 1.568

4.  Hepatitis B in a hospital for the mentally subnormal in South Wales.

Authors:  M A McGregor; V A Cowie; K Wassef; D Veasey; J Munro
Journal:  J Ment Defic Res       Date:  1988-02

5.  Hepatitis-associated-antigen-positive hepatitis in a tuberculosis unit.

Authors:  G R Fitzgerald; H Grimes; M Reynolds; H Hitchcock; C F McCarthy
Journal:  Gut       Date:  1975-06       Impact factor: 23.059

6.  A secondary outbreak of hepatitis B among contacts of drug-abusers in Dublin.

Authors:  D A Kelly; D Carroll; A G Shattock; E O'Connor; D G Weir
Journal:  Ir Med J       Date:  1983-04

7.  Development of an enzyme-linked immunosorbent assay (ELISA) for hepatitis B e antigen and antibody.

Authors:  A M Smith; R S Tedder
Journal:  J Virol Methods       Date:  1981-07       Impact factor: 2.014

8.  Epidemic hepatitis B with delta-antigenaemia among Dublin drug-abusers.

Authors:  A G Shattock; M G Kelly; J Fielding; Y Arthurs
Journal:  Ir J Med Sci       Date:  1982-11       Impact factor: 1.568

9.  Hepatitis in dental professionals.

Authors:  R E Feldman; E R Schiff
Journal:  JAMA       Date:  1975-06-23       Impact factor: 56.272

10.  Increased severity and morbidity of acute hepatitis in drug abusers with simultaneously acquired hepatitis B and hepatitis D virus infections.

Authors:  A G Shattock; F M Irwin; B M Morgan; I B Hillary; M G Kelly; J F Fielding; D A Kelly; D G Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.